FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...
CDC study shows effectiveness of RSV immunization for infants
Mar 7, 2024 · New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
Nirsevimab Resistance Mutations Rare in RSV, Study Shows
1 day ago · Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...
Nirsevimab 89% effective against RSV hospitalization for
1 day ago · graphixchon/ iStock. The preventive monoclonal antibody nirsevimab (Beyfortus) was 89% effective against infant hospitalization in Alaska for respiratory syncytial virus (RSV) in their first RSV season and 76% and 88% effective against medically attended illness for those in their first and second seasons, respectively, estimates a study published yesterday in Morbidity and Mortality Weekly ...
RSV: Jab for winter virus could cut baby hospitalisations by 80
Dec 27, 2023 · Unlike a vaccine, which prompts the body to create antibodies and takes a few weeks to be effective, nirsevimab gives immediate protection.
FDA approves nirsevimab to prevent RSV in infants
Jul 17, 2023 · The monoclonal antibody nirsevimab (brand name Beyfortus) was approved as a single injection for infants born during or entering their first RSV season and young children up to 24 months who remain at risk of severe disease in their second RSV season.
CDC Recommends a Powerful New Tool to Protect Infants from …
Aug 3, 2023 · Nirsevimab, which was approved last month by the U.S. Food and Drug Administration (FDA), is administered as an injection and provides infants and toddlers with antibodies to protect against severe RSV illness. It provides critical protection during a baby’s first RSV season, when they’re most at risk for severe illness.
Press Room - Sanofi US News
Oct 26, 2023 · There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Healthcare Providers: RSV Immunization for Infants and Young …
Nirsevimab is an injectable monoclonal antibody that prevents severe RSV disease in infants and young children. Monoclonal antibodies do not activate the immune system, as would occur with infection or vaccination (active immunization).
Progress at last against RSV - Nature Medicine
Sep 14, 2023 · Nirsevimab, an F-protein-binding monoclonal antibody manufactured by AstraZeneca and Sanofi, exhibited efficacies of over 70% in preventing medically attended …